Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688670 Jiangsu Gdk Biological Technology
41.3500.0000.00%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Per Share Indicator
Net Asset Per Share
-0.40% 16.7398 377.50% 15.9117 361.21% 16.5765 351.96% 16.6065
Basic Earning Per Share
-55.32% 0.63 42.86% -0.2 66.67% -0.03 -53.19% 1.1
Diluted  Earning Per Share
-55.32% 0.63 42.86% -0.2 66.67% -0.03 -53.19% 1.1
Earning Per Share
-44.42% 0.632 44.46% -0.1961 62.59% -0.03 -60.10% 0.937
Diluted Earning Per Share(TTM)
-81.61% 0.4318 -52.06% 1.0058 -56.13% 0.9672 -60.10% 0.937
Capital Surplus Funds Per Share
0.01% 13.0769 2,234.74% 13.0769 2,281.26% 13.0755 2,281.26% 13.0755
Undivided Profit Per Share
-6.30% 2.4098 1.42% 1.5817 22.66% 2.2478 19.09% 2.2778
Operating Cash Flow Per Share
-3.10% 0.2779 -74.34% 0.2695 -87.74% 0.0697 -28.79% 1.181
Enterprise FCF Per Share
115.03% 1.414 270.81% 2.1433 190.45% 0.715 -54.97% -9.8482
Shareholder FCF Per Share
104.95% 0.8799 130.34% 1.8478 130.78% 0.6013 -118.29% -18.3205
EBIT Per Share
-51.78% 0.7023 54.16% -0.1421 85.49% -0.0066 -68.98% 1.0353
Profitability
ROE Weighted
-67.33% 3.800% 88.12% -1.200% 93.08% -0.180% -94.79% 10.890%
ROE
-44.20% 3.775% 88.37% -1.232% 91.89% -0.181% -91.17% 5.643%
ROA
-60.99% 3.103% 66.08% -1.014% 77.59% -0.151% -75.31% 6.512%
ROIC
-65.13% 3.676% 75.28% -0.860% 92.51% -0.039% -86.60% 8.897%
Net Profit Ratio
-12.02% 25.239% -44.96% -105.261% -20.23% -21.188% -20.10% 21.021%
Gross Income Ratio
-4.39% 85.236% 4.25% 88.930% 3.78% 89.295% -2.37% 85.424%
EBIT To Total Operating Revenue
-23.65% 28.048% -19.61% -76.255% 53.66% -4.630% -37.89% 23.226%
Period Costs Rate
21.68% 62.946% 65.82% 306.389% 41.94% 155.733% 6.22% 53.184%
Operating Expense Rate
5.31% 34.809% 17.46% 43.459% 3.03% 40.900% -16.51% 29.641%
Admini Expense Rate
107.64% 17.085% 144.43% 153.746% 134.06% 93.637% 56.64% 12.739%
Financial Expense Rate
-110.56% -0.230% -115.01% -3.147% -123.10% -2.461% 13.85% 1.815%
Recurrent Net Profit
-57.14% 40.55M -10.94% -28.7M -3.19% -6.85M -59.34% 65.83M
Operating Profit Ratio
-18.09% 28.300% 13.69% -73.125% 89.08% -2.254% -40.45% 21.405%
EBIT
-51.77% 61.81M 38.90% -12.5M 80.77% -577.31K -58.64% 91.11M
Solvency
Current Ratio
-42.56% 3.176 335.68% 3.9015 385.40% 4.8258 369.91% 4.8255
Quick Ratio
-43.99% 2.9102 373.67% 3.5246 402.76% 4.558 388.69% 4.6992
Debt Equity Ratio
38.19% 24.256% -93.05% 17.724% -91.86% 18.962% -90.92% 20.058%
Interest Cover(T)
-- -- -- -- -- -- -45.45% 12.8204
Shareholders Equity Without Minority Interests To Total Liabilities
-27.64% 412.278% 1,338.30% 564.210% 1,128.12% 527.372% 1,000.86% 498.558%
Shareholders Equity Without Minority Interests To Interest Bear Debt
-- 2.58K% 7,272.87% 3.89K% 11,374.83% 7.29K% 17,763.37% 14.6K%
Long Debt To Working Capital
214.96% 0.08 -- 0.0555 -- 0.092 -95.63% 0.0842
Growth Ability
Sustainable Grow Rate
-90.78% 3.806% -- -- -- -- -- 34.004%
Operating Capacity
Operating Cycle(D/T)
23.95% 849.0242 152.28% 8.17K 199.21% 5.05K 102.81% 512.9212
Inventory Turnover Days(D/T)
14.19% 451.7316 190.12% 5.39K 254.35% 2.8K 52.66% 192.7504
Accounts Receivable Turnover Days(D/T)
37.29% 397.2925 101.39% 2.78K 150.75% 2.25K 152.79% 320.1708
Inventory turnover Rate(T)
-12.42% 0.5977 -65.53% 0.0334 -71.72% 0.0323 -34.50% 1.8677
Accounts Receivable Turnover Rate(T)
-27.16% 0.6796 -50.38% 0.0647 -60.06% 0.0401 -60.44% 1.1245
Current Assets Turnover Rate(T)
-43.87% 0.2164 -75.84% 0.0172 -80.29% 0.0121 -74.15% 0.4927
Total Assets Turnover Rate(T)
-55.68% 0.1229 -76.70% 0.0096 -81.46% 0.0071 -69.10% 0.3098
Fixed Assets Turnover Rate(T)
-33.86% 1.2629 -47.86% 0.0927 -59.46% 0.0694 -31.42% 2.179
Equity Turnover Rate(T)
-62.94% 0.1502 -91.71% 0.0115 -93.22% 0.0085 -94.76% 0.4604
Cash Position
Free Cash Flow
115.03% 124.43M 327.74% 188.61M 220.59% 62.92M -106.63% -866.65M
Net Profit Cash Cover
74.35% 43.970% -- -- -- -- 78.45% 126.031%
Operating Revenue Cash Cover
22.13% 111.654% 29.74% 1058.318% 30.54% 645.140% 133.74% 117.453%
Operating Cash In To Assets
-31.98% 1.364% -84.33% 1.394% -92.66% 0.352% -55.94% 8.207%
Dividend Ability
Dividend Per Share
-- 0.5 -- 0.5 -- -- -- --
Dividend Paid Ratio
-- 0.000% -- -- -- -- -- 0.000%
Retained Earning Ratio
0.00% 100.000% -- -- -- -- 0.00% 100.000%
Capital Structure
Debt Assets Ratio
30.74% 19.521% -79.04% 15.056% -77.22% 15.940% -75.73% 16.707%
Current Assets To Total Assets
-28.68% 52.805% 4.28% 50.593% -1.51% 56.902% -9.27% 60.969%
Non Current Assets To Total Assets
81.79% 47.195% -4.03% 49.407% 2.06% 43.098% 18.99% 39.031%
Fix Assets Ratio
-15.43% 9.118% -55.63% 10.407% -53.40% 10.213% -54.63% 10.379%
Interest Bearing Debt To Total Capital
-- 3.729% -96.17% 2.509% -97.79% 1.354% -98.76% 0.680%
Yield Quality
Net Income From Value Changes To Total Profit
2,001.13% 16.780% -- -- -- -- 4,401.56% 8.639%
Recurrent Net Profit To Net Profit
-22.88% 72.913% -- -- -- -- -23.57% 79.831%
Dupont Analysis
Equity Multipler_DuPont
-16.43% 122.165% -64.72% 118.916% -63.43% 119.510% -83.04% 148.630%
Net Profit of Parent Company OwnersTo Net Profit_DuPont
0.00% 100.000% 0.00% 100.000% 0.00% 100.000% 0.00% 100.000%
Net Profit To Total Operating Revenue_DuPont
-12.02% 25.239% -44.96% -105.261% -20.23% -21.188% -20.10% 21.021%
Net Profit To Total Profit_DuPont
7.52% 89.252% -- -- -- -- 33.60% 98.166%
Total Profit To EBIT_DuPont
7.17% 100.820% -- -- -- -- -3.70% 92.200%
EBIT To Total Operating Revenue_DuPont
-23.65% 28.048% -19.61% -76.255% 53.66% -4.630% -37.89% 23.226%
Currency Unit
CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company was founded in December 2008, with a registered capital of 88 million yuan. The company is located in Taizhou, Jiangsu Province, a famous city with a long history in the Yangtze River Delta, and is located in the national pharmaceutical high-tech industry and technology development zone. The company is a biological high-tech enterprise integrating scientific research, production, management and service of human vaccine, with perfect technical development strength, technical level, production and testing equipment, scientific and standardized management and quality assurance system. The company focuses on the R & D, production and sales of human vaccines. The main products include 10 kinds of human vaccine products for the prevention of five infectious diseases, including influenza, rabies, chicken pox, herpes zoster and pneumonia.
CEO: Jun Yu
Market: --
Listing Date: 08/02/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist